Neutrophil, Lymphocyte Ratio May Predict Survival in Head and Neck Cancer

Share this content:
Neutrophil-to-lymphocyte ratio may be a strong predictor of overall survival in head and neck carcinomas.
Neutrophil-to-lymphocyte ratio may be a strong predictor of overall survival in head and neck carcinomas.

Neutrophil-to-lymphocyte ratio (NLR) may be a strong predictor of overall survival in oral, pharyngeal, and laryngeal squamous cell carcinomas, according to a recent study published online in the journal Head & Neck.1

Researchers led by Saleh Rachidi, BS, of the Medical University of South Carolina in Charleston conducted a retrospective study of pretreatment neutrophil and lymphocyte counts as well as NLR in correlation with overall survival in patients with head and neck cancer.

“Current prognostic criteria are insufficient in predicting outcomes in head and neck cancer, necessitating new, readily available biomarkers,” the authors noted.

They found that patients in the highest tertile of neutrophil count as well as those in the lowest tertile of lymphocyte count were associated with shorter survival than the rest of the examined population.

RELATED: No Definite Symptom Index for Recurrence in Head and Neck Cancer, Small Study Suggests

Upon multivariate analysis, those in the highest tertile of NLR were found to be at a higher risk compared to those in the lowest tertile.

In addition, NLR was found to be lower among patients with human papillomavirus (HPV)-positive tumors compared to those with HPV-negative tumors, and it was also predictive of survival in both types.

Reference

  1. Rachidi S, Wallace K, Wrangle JM, et al. Neutrophil-to-lymphocyte ratio and overall survival in all sites of head and neck squamous cell carcinoma. Head Neck. [published online ahead of print September 28, 2015]. DOI: 10.1002/hed.24159.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters